Syngoi Technologies

Executive Summary

Syngoi Technologies is a Spanish biotechnology company founded in 2020 and headquartered in Barcelona, with operational facilities in Zamudio, Bilbao. The company has developed a proprietary cell-free enzymatic process for the optimized manufacturing of linear synthetic DNA. This technology addresses a critical bottleneck in the production of genetic medicines, offering a reliable and scalable source of synthetic DNA at lower cost compared to traditional methods. By focusing on linear DNA (as opposed to plasmid DNA), Syngoi aims to enable advanced therapies such as mRNA vaccines, gene editing, and cell therapies, which require high-quality synthetic DNA as a fundamental raw material. The company's cell-free approach eliminates the need for microbial fermentation, reducing production times and contamination risks, and positioning Syngoi as a potential key enabler of the genetic medicine supply chain. The global synthetic biology and genetic medicine markets are growing rapidly, driven by innovations in CRISPR, mRNA therapeutics, and personalized medicine. Syngoi's technology aligns with industry needs for cost-effective, scalable, and reproducible DNA manufacturing. Currently operating as a private entity, the company is likely seeking partnerships and funding to scale its manufacturing capabilities and expand its customer base. While still in early stages, Syngoi's unique value proposition and location in Spain's growing biotech hub position it for growth as demand for synthetic DNA surges. However, competition from established players and technology risks remain considerations.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Funding Round70% success
• Q4 2026Strategic Partnership with Pharma/Biotech for DNA Supply60% success
• TBDScale-Up of Manufacturing Capacity and Facility Expansion80% success